Prehospital Levetiracetam Use in Adults With Status Epilepticus: Results of a Multicenter Registry
- Author:
Lothar BURGHAUS
1
;
Marie MADLENER
;
Felix KOHLE
;
Emanuel F. BRUNO
;
Volker LIMMROTH
;
Gereon R. FINK
;
Michael P. MALTER
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Clinical Neurology 2023;19(4):365-370
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:and Purpose Status epilepticus (SE) is a neurological emergency due to prolonged seizure activity or multiple seizures without full recovery in between them. Prehospital SE management is crucial since its duration is correlated with higher morbidity and mortality rates. We examined the impact of different therapeutic strategies in the prehospital setting with a focus on levetiracetam.
Methods:We initiated the Project for SE in Cologne, a scientific association of all neurological departments of Cologne, the fourth-largest city in Germany with around 1,000,000 inhabitants. All patients with an SE diagnosis were evaluated over 2 years (from March 2019 to February 2021) to determine whether prehospital levetiracetam use had a significant effect on SE parameters.
Results:We identified 145 patients who received initial drug therapy in the prehospital setting by professional medical staff. Various benzodiazepine (BZD) derivatives were used as first-line treatments, which were mostly used in line with the recommended guidelines. Levetiracetam was regularly used (n=42) and mostly in combination with BZDs, but no significant additional effect was observed for intravenous levetiracetam. However, it appeared that the administered doses tended to be low.
Conclusions:Levetiracetam can be applied to adults with SE in prehospital settings with little effort. Nevertheless, the prehospital treatment regimen described here for the first time did not significantly improve the preclinical cessation rate of SE. Future therapy concepts should be based on this, and the effects of higher doses should in particular be reexamined.
